Minoxidil
Minoxidil is a topical and low-dose oral medication for androgenetic alopecia (male and female pattern hair loss). It was originally an oral antihypertensive and is now the only FDA-approved topical hair-loss treatment for women alongside finasteride for men.
- Chemical formula
- C9H15N5O
- CAS number
- 38304-91-5
- ATC code
- D11AX01
- Molecular weight
- 209.25 g/mol
- Drug class
- Hair-loss treatment / vasodilator
- Also known as
- Rogaine, Loniten, Regaine
What is it?
Minoxidil was developed as an oral antihypertensive in the 1970s, and its hypertrichosis side effect led to a topical reformulation for hair loss as Rogaine (Upjohn) in 1988. It is the only FDA-approved topical treatment for androgenetic alopecia, available over the counter in 2% and 5% solutions and 5% foam, alongside oral Loniten for severe hypertension. Low-dose oral minoxidil for hair loss is increasingly used off-label as an effective alternative when topical formulations are inconvenient or ineffective.
Mechanism of action
Minoxidil is a potassium channel opener that produces arteriolar vasodilation. Its effect on hair follicles is incompletely understood but appears to prolong the anagen (growth) phase, enlarge miniaturised follicles and increase blood flow to the dermal papilla. The active metabolite minoxidil sulfate is generated by sulfotransferase enzymes in the scalp, and individual variation in this enzyme partly explains why some people respond and others do not.
Pharmacokinetics
Topical absorption is limited (~1.4% of applied dose) but enough to occasionally produce systemic effects. Oral bioavailability is 90%, with peak plasma at 1 hour and elimination half-life of 3–4 hours. Hepatic metabolism via sulfation produces the active sulfate metabolite. Local hair-follicle sulfotransferase activity is the rate-limiting step for cosmetic effect, which is why some non-responders to topical minoxidil respond to oral.
Indications
Topical minoxidil is approved for androgenetic alopecia in men and women, including post-menopausal women. Oral minoxidil at 2.5–40mg is approved for severe hypertension, but low-dose oral (0.25–5mg) is widely used off-label for hair loss. Effectiveness varies — about 40% of users see meaningful regrowth, 40% see stabilisation and 20% continue to lose hair. Continuous use is required to maintain effect; benefit is lost within months of stopping.
Safety profile
Topical adverse effects are mostly local: scalp irritation, dermatitis, paradoxical shedding in the first weeks (which usually resolves), and unwanted facial hair from inadvertent transfer. Systemic effects from topical use are rare. Oral minoxidil at low hair-loss doses can cause fluid retention, ankle oedema, hypertrichosis on body and face, dizziness and rarely pericardial effusion at higher doses. According to clinical practice, baseline blood pressure and clinical follow-up are recommended for oral minoxidil.
Products containing this ingredient
Frequently asked questions
Why does minoxidil cause initial hair shedding? ▾
When minoxidil is started, follicles in the resting (telogen) phase are pushed into a new growth (anagen) phase. The transition expels the existing telogen hair, producing a temporary increase in shedding for 4–8 weeks. According to clinical practice, this paradoxical shedding is a sign the medication is working and should not prompt discontinuation.
Is oral minoxidil safer than topical for hair loss? ▾
Oral and topical minoxidil have different side effect profiles, not different safety. Topical minoxidil has more local effects (scalp irritation) and less systemic risk, while low-dose oral minoxidil has more systemic effects (fluid retention, body hair) and more reliable absorption. According to recent dermatology literature, low-dose oral minoxidil is broadly comparable in efficacy and well tolerated in most users.
Can minoxidil and finasteride be used together? ▾
Yes — combination therapy with topical or oral minoxidil and oral finasteride is standard practice for moderate to severe male pattern hair loss because the two work by different mechanisms (vasodilator vs DHT-suppressor). According to current guidelines, combination therapy is more effective than either alone, though side effect profiles add.
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.